ストックスクリーナーアプリを入手
19.38
7.09%
-1.48
アフターアワーズ：
19.25
-0.13
-0.67%
前日終値:
$20.86
開ける：
$20.58
24時間の取引高:
22.25M
Relative Volume:
0.71
時価総額：
$4.42B
収益：
$2.35B
当期純損益:
$128.37M
株価収益率:
37.12
EPS:
0.5221
ネットキャッシュフロー:
$57.42M
1週間 パフォーマンス:
-11.99%
1か月 パフォーマンス:
+33.47%
6か月 パフォーマンス:
-66.82%
1年 パフォーマンス:
-39.29%
1日の値動き範囲:
$19.18
$20.60
1週間の範囲:
$19.18
$23.10
52週間の値動き範囲:
$13.74
$70.43
Hims Hers Health Inc Stock (HIMS) Company Profile
Compare HIMS vs TAK, ZTS, HLN, TEVA, UTHR
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
HIMS
Hims Hers Health Inc
|
19.38 | 4.75B | 2.35B | 128.37M | 57.42M | 0.5221 |
TAK
Takeda Pharmaceutical Co Adr
|
17.91 | 57.06B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
113.35 | 49.23B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.80 | 43.52B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
28.74 | 34.68B | 17.41B | 1.43B | 1.00B | 1.2182 |
UTHR
United Therapeutics Corp
|
522.83 | 23.34B | 3.18B | 1.33B | 1.04B | 27.90 |
Hims Hers Health Inc Stock (HIMS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-10 | アップグレード | BofA Securities | Underperform → Neutral |
| 2026-03-10 | アップグレード | Citigroup | Sell → Neutral |
| 2026-03-09 | アップグレード | Needham | Hold → Buy |
| 2026-02-24 | ダウングレード | BTIG Research | Buy → Neutral |
| 2026-01-12 | 開始されました | Evercore ISI | In-line |
| 2025-12-09 | 開始されました | Barclays | Overweight |
| 2025-10-21 | 開始されました | KeyBanc Capital Markets | Sector Weight |
| 2025-06-23 | ダウングレード | Needham | Buy → Hold |
| 2025-06-04 | 繰り返されました | Needham | Buy |
| 2025-04-29 | ダウングレード | TD Cowen | Buy → Hold |
| 2025-02-18 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2025-01-10 | ダウングレード | Citigroup | Neutral → Sell |
| 2025-01-07 | 開始されました | BTIG Research | Buy |
| 2024-12-17 | 開始されました | Morgan Stanley | Overweight |
| 2024-11-14 | ダウングレード | BofA Securities | Buy → Underperform |
| 2024-08-22 | 開始されました | Needham | Buy |
| 2024-08-09 | ダウングレード | Imperial Capital | Outperform → In-line |
| 2024-05-22 | ダウングレード | Citigroup | Buy → Neutral |
| 2024-04-16 | ダウングレード | Jefferies | Buy → Hold |
| 2024-04-10 | 開始されました | Canaccord Genuity | Buy |
| 2024-02-28 | アップグレード | Imperial Capital | In-line → Outperform |
| 2024-02-26 | 開始されました | Leerink Partners | Market Perform |
| 2023-12-07 | 開始されました | Imperial Capital | In-line |
| 2023-07-28 | 開始されました | TD Cowen | Outperform |
| 2023-04-11 | 開始されました | Robert W. Baird | Neutral |
| 2023-02-09 | アップグレード | Jefferies | Hold → Buy |
| 2022-11-08 | アップグレード | BofA Securities | Neutral → Buy |
| 2022-11-08 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2022-10-17 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2022-09-07 | 開始されました | Truist | Hold |
| 2022-07-15 | 開始されました | SVB Leerink | Underperform |
| 2022-04-14 | 開始されました | Guggenheim | Buy |
| 2022-04-01 | 再開されました | Credit Suisse | Outperform |
| 2022-03-10 | 開始されました | Deutsche Bank | Hold |
| 2021-12-02 | 開始されました | Jefferies | Hold |
| 2021-11-11 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2021-07-06 | 開始されました | BofA Securities | Neutral |
| 2021-05-20 | アップグレード | Credit Suisse | Neutral → Outperform |
| 2021-04-21 | 開始されました | Truist | Hold |
| 2021-03-09 | 開始されました | Credit Suisse | Neutral |
| 2021-03-02 | アップグレード | Citigroup | Neutral → Buy |
| 2021-02-17 | 開始されました | Citigroup | Neutral |
| 2021-02-12 | 開始されました | Piper Sandler | Neutral |
| 2021-02-08 | 開始されました | Tigress Financial | Buy |
すべてを表示
Hims Hers Health Inc (HIMS) 最新ニュース
Hims & Hers Stock Decline Amid Legal Battles and Strategic Repositioning - StocksToTrade
Enovis, Neogen, Humana, LifeStance Health Group, and Hims & Hers Health Stocks Trade Down, What You Need To Know - The Globe and Mail
Hims & Hers Health Launches Offering Featuring Novo Nordisk Products - marketscreener.com
From Breaking Stigma to Building the Future of Health - Hims & Hers Newsroom
Hims & Hers Health | SCHEDULE 13G/A: Others - Moomoo
Hims & Hers: The Reset Before The Next Inflection (NYSE:HIMS) - Seeking Alpha
Hims & Hers Health (HIMS) price target decreased by 14.58% to 25.63 - MSN
CCORF Maintains Hims & Hers Health(HIMS.US) With Buy Rating, Maintains Target Price $30 - Moomoo
Canaccord reiterates Hims and Hers stock rating on Novo launch - Investing.com
Canaccord reiterates Hims and Hers stock rating on Novo launch By Investing.com - Investing.com India
Oil Surge Past $100, S&P 500 Changes & AI Trends | Market AnalysisNews and Statistics - IndexBox
Hims & Hers shifts business model after Novo deal - thestreet.com
Hims and Hers stock price target maintained at $23 by BofA Securities - Investing.com South Africa
What's Happening With Novo Nordisk Stock Today? - Benzinga
Hims & Hers Health (HIMS) Expands Offerings with Novo Nordisk Me - gurufocus.com
-3.50% for Hims & Hers Health stock as daily low tests immediate support - Traders Union
Hims & Hers Health starts selling Novo Nordisk's Wegovy, Ozempic - Seeking Alpha
Why is Hims & Hers Health stock down today? - Traders Union
Hims & Hers adds Novo Nordisk GLP-1 medications to platform - Investing.com
Hims Inc.Novo Nordisk’s FDA-Approved GLP-1s Now Available With Hims & Hers - HIMS Investor Relations
Novo Nordisk’s FDA-Approved GLP-1s Now Available With Hims & Hers - The Joplin Globe
Wegovy® Pill and Wegovy® Pen Now Available with Hims & Hers - Hims & Hers Newsroom
It’s Easier Than Ever To Get A Prescription Online. That Might Be A Problem - MedShadow Foundation
HIMS Stock In Spotlight After Hims & Hers Adds Novo’s GLP-1 Treatments To Its Platform - Stocktwits
Hims & Hers Health Options Spot-On: On March 25th, 136.26K Contracts Were Traded, With 1.06 Million Open Interest - Moomoo
Hims & Hers: Distressed Valuations Will Not Last For Long (NYSE:HIMS) - Seeking Alpha
HIMS Investors Have Opportunity to Join Hims & Hers Health, Inc. Fraud Investigation with the Schall Law Firm - GlobeNewswire
HIMS vs. DOCS: Which Digital Health Stock Offers Better Upside Now? - TradingView
With Legal Overhang Behind, Hims Looks To Drive Growth via Novo Partnership and International Push - Morningstar
Hims & Hers Health stock slips 3.33% as resistance holds and sellers dominate near $20.00 support - Traders Union
HIMS Stock | Hims & Hers Health, Inc. Price, Quote, News & Analysis - TipRanks
Oluyemi Okupe Sells 9,217 Shares of Hims & Hers Health (NYSE:HIMS) Stock - MarketBeat
Hers Review: Is It Right for You? - Healthline
Hims & Hers Faces Multifaceted Challenges as Investor Confidence Wavers - AD HOC NEWS
Okupe, Hims & Hers health CFO, sells $219k in shares - Investing.com
[Form 4] Hims & Hers Health, Inc. Insider Trading Activity - Stock Titan
Hims & Hers Health, Inc. (HIMS) Dips More Than Broader Market: What You Should Know - Yahoo Finance
Canaccord Lowers Hims & Hers Health, Inc. (HIMS) Price Target Patent Amid Dispute and FDA Scrutiny - MSN
Hims & Hers Faces Legal Scrutiny Over Wegovy Sales - StocksToTrade
Hims & Hers Health Options Spot-On: On March 24th, 116.22K Contracts Were Traded, With 1.04 Million Open Interest - Moomoo
Hims & Hers Health (HIMS) Valuation After Novo Nordisk Weight Loss Deal And Product Exit - Yahoo Finance
INSP vs. HIMS: Which Stock Should Value Investors Buy Now? - Yahoo! Finance Canada
-3.85% for Hims & Hers Health stock as mixed momentum highlights limited upside - Traders Union
Osborne Clarke advises Hims & Hers Health, Inc on the UK, German and Dutch aspects of its acquisition of Eucalyptus - Osborne Clarke
Hims & Hers (HIMS) tumbles 8.86% on market bloodbath, profit-taking - MSN
Investor relations - HIMS Investor Relations
Hims & Hers Health Options Spot-On: On March 23rd, 125.05K Contracts Were Traded, With 1.42 Million Open Interest - Moomoo
Hims & Hers Expands Integrated Digital Healthcare Ecosystem - The Globe and Mail
Are GLP-1 Drugs Becoming a Meaningful Revenue Driver for CAH Stock? - TradingView
Hims & Hers Health, Inc. (HIMS) is attracting investor attention: Here is what you should know - MSN
What triggered Hims & Hers Health shares' latest price surge - Traders Union
Hims Hers Health Inc (HIMS) 財務データ
収益
当期純利益
現金流量
EPS
2.11%
1.06%
大文字化:
|
ボリューム (24 時間):